The outlook for drug development to treat rare diseases looks encouraging, offering hope to the 300 million people globally facing the significant challenges of these often-overlooked condi
There are significant opportunities for pharma and biotech companies to support patients in the Middle East, but how do companies navigate such a culturally diverse region?
Pharma companies who want to keep the prices of their medicines private in Germany may soon be able to do so – as long as they meet certain conditions.
In an on-site interview at Reuters Pharma Europe in Barcelona, this week’s podcast saw Tommy Bramley, SVP of market access and healthcare consulting at Cencora, discuss revitalising Europe’
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours and developments that have occurred since inaugural discussions last year